Table 1.

Patient characteristics receiving infliximab for grade 3 and 4 pneumonitis

Case	Age, Years	Sex	Cancer	Immunotherapy	Corticosteroid, mg/kg*	Time, Days^	Ventilatory Support, FiO2%	irAEs	Bronchoscopy, Lymphocytes, %	Outcome
1	66	M	Melanoma	Ipilimumab	1.2	2	Nasal cannula, 24%	–	No	Improved
2	66	M	Pancreatic	Ipilimumab	1.3	5	High-flow, 45%	Hepatic&	No	Improved
3	52	F	AML	Ipilimumab, nivolumab	3.3	9	High-flow, 60%	–	Yes‡	Improved
4	69	F	AML	Ipilimumab, nivolumab	1.1	7	MV, 90%	Dermatologic, gastrointestinal	Yes‡	Improved
5	79	M	AML	Nivolumab	2.4	34	High-flow, 50%	Renal	Yes, 13	Death+
6	72	M	AML	Ipilimumab, nivolumab	1.1	Chronic	High-flow, 30%	Hematologic	Yes, 26	Death+
7	72	F	MDS	Ipilimumab, nivolumab	2.0	2	BiPAP, 70%	Dermatologic	Yes, 18	Death
8	68	F	Lung	Nivolumab	0.8	9	High-flow, 75%	–	No	Death
9	61	M	Urothelial	Nivolumab	1.2	7	High-flow, 75%	–	Yes‡	Death

AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; MV: mechanical ventilation; BiPAP: bi-level positive airway pressure

^*Maximal dosage (all patients were initiated on intravenous methylprednisone, and those that improved were transitioned to oral prednisone)

^{^}Time from steroid administration to infliximab dosing

⁺Initially had improvement

^&irAE occurred prior to pneumonitis

^‡No bronchoalveolar lavage cell count and differential performed